GeneDx to Report Fourth Quarter 2023 Financial Results on Tuesday, February 20, 2024 

STAMFORD, Conn., Feb. 01, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will release financial results for the fourth quarter of 2023 after the market closes on Tuesday, February 20, 2024. Management will host a conference call that day to discuss 2023 financial and operating results and share full year 2024 guidance at 4:30 p.m. Eastern Time. 

Conference Call Details 
Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the “Events” section of the GeneDx investor relations website at

About GeneDx 
GeneDx (Nasdaq: WGS) delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its industry-leading exome and genome testing and interpretation, fueled by one of the world’s largest rare disease data sets. For more information, please visit and connect with us on LinkedInFacebookTwitter and Instagram.

Investor Relations Contact: 

Media Contact: